Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.

Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage. The candidate, which will be developed by Poolbeg as POLB 002, was developed at the University of Warwick and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock.

Press release (17 January 2022)